Point Therapeutics to Present at Friedman Billings Ramsey 2006 Growth Investor Conference
May 30 2006 - 6:44AM
Business Wire
Point Therapeutics, Inc. (NASDAQ:POTP) announced that Don Kiepert,
President and CEO, will present at the Friedman Billings Ramsey
2006 Growth Investor Conference at the Grand Hyatt Hotel in New
York City on Thursday, June 1, 2006 at 9:00 a.m. Eastern Time. Mr.
Kiepert will review key research and development accomplishments
and discuss upcoming corporate initiatives. A live Web cast of the
presentation will be available on the Company's Web site,
www.pther.com. About Point Therapeutics, Inc.: Point is a
Boston-based biopharmaceutical company developing a portfolio of
dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2
diabetes and as vaccine adjuvants. Point is currently studying its
lead product candidate, talabostat, in two Phase 3 trials in
non-small cell lung cancer. Point is also studying talabostat in
several Phase 2 trials, including as a single-agent in metastatic
melanoma, in combination with cisplatin in metastatic melanoma, in
combination with rituximab in advanced chronic lymphocytic
leukemia, and in combination with gemcitabine in metastatic
pancreatic cancer. In addition, Point's portfolio includes two
other DPP inhibitors in preclinical development--PT-630 for type 2
diabetes, and PT-510 as a vaccine adjuvant.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Point Therapeutics (MM) (NASDAQ): 0 recent articles
More Point Therapeutics, Inc. News Articles